Best Life Sciences Companies in Hamburg, Germany
The 71 best Life Sciences companies in Hamburg, Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Topas Therapeutics.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Hamburg
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Topas Therapeutics Developer of nanoparticle-based therapeutics for immunology disorders | $69M | 58 mo ago | Series B | — | 2016 | WordPressMySQLPHP+7 | 54 patents Targeted nanoparticle delivery systems for antigens and viral vectors in immunotherapy | — |
| 2 | Indivumed Specimen biobank, Drug and biomarker service provider | $48M | 101 mo ago | Funding Raised | — | 2002 | StoryblokApple iCloud MailMicrosoft 365+19 | 71 patents Predictive biomarkers and diagnostics for colorectal cancer therapy response | — |
| 3 | Breakpoint Therapeutics Provider anti-cancer drug based on DNA repair mechanism | $34M | 83 mo ago | Series A | — | 2019 | — | 15 patents Inhibiting DNA repair enzymes (polymerase θ, Werner helicase) for cancer therapeutics | — |
| 4 | Evotec AI-driven life science company accelerating drug discovery and development 91Talent top 18%Funding top 21%Fin. health top 21%Patents top 26% All 13 signals ▾Talenttop 18% Fundingtop 21% Fin. healthtop 21% Patentstop 26% Newstop 26% Markettop 27% Partnerstop 28% Moattop 29% Techtop 33% Growthtop 35% Globaltop 35% Innovationtop 40% AItop 45% Talent: Analyst team rating 4/5 · 13 leadership moves in 12 mo Funding: Raised $25.0M across 16 rounds · 16 rounds over 28 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 91/100 | $25M | 5 mo ago | Public | — | 1993 | Apple iCloud MailMicrosoft 365Svelte+22 | 357 patents Small-molecule therapeutics targeting oncology, infectious diseases, and anti‑fibrotic treatments | 1 launch · 1 award |
| 5 | Mindpeak Provider of AI-based pathological analysis platform 48AI top 20%Funding top 35%Patents top 42%Moat top 42% All 9 signals ▾AItop 20% Fundingtop 35% Patentstop 42% Moattop 42% Innovationtop 43% Talentbottom 49% Techbottom 41% Globalbottom 39% Marketbottom 34% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $18.3M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $18M | 20 mo ago | Series A | Felix Faber Co-Founder & CEO | 2017 | WebflowThree.jsGSAP+15 | 7 patents AI-driven histopathology image analysis and region-of-interest selection for medical diagnostics | — |
| 6 | GeneQuine Developer of gene therapies for the treatment of musculoskeletal disorders | $10M | 64 mo ago | Series A | Kilian Guse Co-Founder & CEO | 2012 | — | — | — |
| 7 | Mo:re Developer of 3D cell culture robot for medical research | $2M | 14 mo ago | Seed | David Hackenberger Co-Founder | 2023 | WordPressMySQLPHP+19 | — | 2 launchs · 1 partnership |
| 8 | Abviris Provider of diagnostics solutions for HPV infections | $2M | 63 mo ago | Seed | Stefan Raupach Co-Founder & General Manager | 2014 | — | — | — |
| 9 | AmpTec Provider of products for RNA biology | $188K | 54 mo ago | Acquired | Guido Krupp Co-Founder | 2005 | — | 11 patents RNA synthesis and amplification technologies for nucleic acid production | — |
Top 12 Life Sciences companies in Hamburg
#1
Public · Hamburg, Hamburg · founded 1993 · 252 employees$25Mraised▾
AI-driven life science company accelerating drug discovery and development. It is focused on pioneering drug discovery and preclinical development using advanced technologies, deep disease expertise, and integrated R&D platforms. It accelerates the creation of new therapies across modalities, including small molecules and biologics, to bring life-changing medicines to patients faster.
- Jan 2026Grant (prize money)—
- May 2025Grant (prize money)$2.5M
- Apr 2025Grant (prize money)$654.4K
- Jun 2023Grant (prize money)$1.7M
#2
Series A · Hamburg, Hamburg · founded 2017 · 28 employees$18.3Mraised▾
MindPeak provides a platform for pathological analysis. The platform helps in automating microscopical and pathological analysis. The platform uses artificial intelligence and deep learning for their analysis and the company is focused on the diagnosis of cancer.
- Sep 2024Series A$15.3M
- Aug 2020Grant (prize money)$1.6M
- Jun 2020Grant (prize money)$2.2M
- Sep 2019Seed$3M
#3
Seed · Hamburg, Hamburg · founded 2023$2.5Mraised▾
Developer of 3D cell culture robot for medical research. It offers robotic and software platform for automated and AI-assisted cultivation processes forcell survival and standardisation for research publications and regulatory approval. It is used for cell therapy, drug development, screening, genetic engineering, and others.
- Mar 2025Seed$2.5M
#4
Series B · Hamburg, Hamburg · founded 2016 · 14 employees$68.5Mraised▾
Developer of nanoparticle-based therapeutics for immunology disorders. The company's pipeline drug candidates include TPM 203 for pemphigus Vulgaris, TPM 501/502 for celiac disease, and anti-drug immune response.
- Jul 2021Series B$21.3M
- Mar 2021Grant (prize money)$492.1K
- Oct 2020Series B$25.8M
- Apr 2020Grant (prize money)$290.8K
#5
Funding Raised · Hamburg, Hamburg · founded 2002 · 178 employees$48Mraised▾
Indivumed is an integrated oncology company that has the ability to collect and preserve biospecimens as quickly as possible for clinical trials. The company generates biospecimens that consist of molecular patterns similar to the one present in human body. The company offers tumor tissue specimens and tissue-related molecular analytical services. In addition, it offers drug and biomarker development services including immunohistochemistry, phosphoprotein profiling, drug profiling, capture microdissection and genomics services.
- Jan 2018Conventional Debt$48M
- Nov 2009Grant (prize money)—
#6
Series A · Hamburg, Hamburg · founded 2019 · 5 employees$33.7Mraised▾
Breakpoint Therapeutics develops anti-cancer drugs based on DNA repair mechanisms. It is the spin-off company of Evotec SE. Its oncolytic drugs developed by them interferes with DNA repair and replication stress tolerance pathways. It targets the DNA Damage Response (DDR) in cancer cells.
- Jul 2019Series A$33.7M
#7
Series A · Hamburg, Hamburg · founded 2012 · 6 employees$9.9Mraised▾
Developer of gene therapies for the treatment of musculoskeletal disorders
#8
Seed · Hamburg, Hamburg · founded 2014 · 5 employees$2.4Mraised▾
Moving from cell to blood based HPV cancer screening, Abviris has developed a new patented generation of Immune Oncology Diagnostics for the early detection of HPV induced cancer, allowing a blood based entire body screen within minutes by using just one drop of blood. Abviris addresses the globally increasing problem of cancer caused by the human papillomavirus (HPV). We are dedicated to improving the clinical outcomes of patients and enable clinicians worldwide to fight HPV-induced tumours, including head and neck cancer, penile and anal tumours, vaginal and vulvar cancer and of course cervical cancer. Our patented diagnostics provide a key contribution to a favourable prognosis, such as e
#9
Acquired · Hamburg, Hamburg · founded 2005 · 40 employees$188.1Kraised▾
Provider of products for RNA biology. The product portfolio of the company comprises RNA isolation and mRNA amplification kits, guide RNA for CRISPR, synthetic long RNAs, and DNAs as well as functional mRNAs.
- Dec 2021Grant (prize money)$40.5K
- Feb 2021Grant (prize money)$102.4K
- Mar 2020Grant (prize money)$45.2K
#10
Public · Hamburg, Hamburg · founded 2006 · 7 employees—raised▾
Immuneservice is focussed on developing biological medicines that activate that body’s own immune system to eliminate cancer and viral infections. Its medicines are based on Interleukin-2, an essential immune hormone that occurs naturally in the body. Its initial focus is on renal cancer and melanoma and is developing therapeutic methods that are especially well tolerated by patients which claim to preserve the quality of life during therapy and providing access to these innovative methods with the potential to cure.
- Dec 2019Series C—
- Feb 2015Series C—
- Jan 2008Seed—
#11
Seed · Hamburg, Hamburg · founded 2016 · 17 employees—raised▾
Smart thermometer for fertility tracking. The company's product includes a device that measures the basal body temperature of the user and sends the data to the connected app via Bluetooth. The user is supposed to measure the basal body temperature every morning. Based on the data collected, the app calculates user's fertile days according to the temperature curve. The device is available in three variants for measurement in the ear, in the mouth or vagina.
- Oct 2017Seed—
#12
Funding Raised · Hamburg, Hamburg · founded 2015—raised▾
Upcyte Technologies is a life science company specialized in the controlled, scalable propagation and standardization of quasi (human) primary cell products to develop cost-effective cell based assays to be used in a wide range of applications in life science research and pharmaceutical development. With their proprietary upcyte® technology, they are able to expand human primary cells thereby generating proliferating assay-ready cells from various human healthy or diseased tissues. The well characterized cell strains retain primary-like metabolic and physiological features as well as the typical cell-type specific morphology. In Oct 2015, Upcyte receives a ZIM-BMWi grant together with TU Ilmenau and Heidelberg University, to develop a 3D Culture model to determine liver toxicity in drug development. The virtually unlimited availability of differentiated cells and their long viability period gives upcyte hepatocytes an advantage over other commonly used cells. Upcyte's technology allows controlled proliferation beyond the typical life span of primary cells without either immortalization or loss of differentiation properties. In July 2016, Upcyte entered into a distribution partnersh
- Apr 2017Grant (prize money)—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Hamburg researches in biotechnology
- University Medical Center Hamburg-Eppendorf11
- Universität Hamburg10
- HAW Hamburg3
- MSH Medical School Hamburg – University of Applied Sciences and Medical University2
- Hamburg Institut2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.